Lubeck D P, Kim H, Grossfeld G, Ray P, Penson D F, Flanders S C, Carroll P R
Department of Urology and UCSF/Mt. Zion Comprehensive Cancer Center, University of California, San Francisco, USA.
J Urol. 2001 Dec;166(6):2281-5.
Understanding the potential consequences of racial differences in prostate cancer outcomes, from survival rates to quality of life considerations, is important for the clinician and patient. We examined demographic, clinical and health related quality of life data comparing black with white patients just after treatment of prostate cancer and 1 year later.
We analyzed data on 1,178 patients who were newly diagnosed with prostate cancer in the Cancer of the Prostate Strategic Urologic Research Endeavor, a national observational database of men recruited from 35 community and academic urology practices throughout the United States. Patient demographics, clinical characteristics and validated health related quality of life questionnaires were reviewed. A total of 958 white and 161 black patients with prostate cancer who completed at least 2 surveys were compared.
The black patients were younger, and had lower income and education levels than white patients. Controlling for age, education and income differences, black patients generally had worse clinical characteristics at presentation and lower baseline health related quality of life data scores in most generic and disease specific categories at treatment. The most notable exception was sexual function, which was the only score that was higher in black patients at treatment. With time, health related quality of life improved in both groups but black patients had slower rates of improvement for general health, bodily pain, physical function, role function, disease worry and bowel function. They continued to have higher sexual function.
Significant differences exist in clinical presentation, sociodemographic characteristics, and health related quality of life between black and white men with prostate cancer. These health related quality of life differences remain after treatment. Physicians should not assume that outcomes in black men would be similar to other patients.
了解前列腺癌治疗结果中种族差异的潜在后果,从生存率到生活质量考量,对临床医生和患者都很重要。我们检查了前列腺癌治疗刚结束时以及1年后黑人和白人患者的人口统计学、临床和健康相关生活质量数据。
我们分析了前列腺癌战略泌尿学研究计划中1178例新诊断为前列腺癌患者的数据,该计划是一个全国性观察数据库,招募了来自美国35个社区和学术泌尿外科诊所的男性。回顾了患者的人口统计学、临床特征以及经过验证的健康相关生活质量问卷。比较了总共958例完成至少2次调查的白人前列腺癌患者和161例黑人前列腺癌患者。
黑人患者比白人患者更年轻,收入和教育水平更低。在控制年龄、教育和收入差异后,黑人患者在就诊时通常具有更差的临床特征,并且在治疗时大多数通用和疾病特定类别中的基线健康相关生活质量数据得分更低。最显著的例外是性功能,这是治疗时黑人患者唯一得分更高的项目。随着时间推移,两组的健康相关生活质量都有所改善,但黑人患者在总体健康、身体疼痛、身体功能、角色功能、疾病担忧和肠道功能方面的改善速度较慢。他们的性功能仍然较高。
患有前列腺癌的黑人和白人男性在临床表现、社会人口统计学特征以及健康相关生活质量方面存在显著差异。这些健康相关生活质量差异在治疗后仍然存在。医生不应假定黑人男性的治疗结果会与其他患者相似。